RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
1200. Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ.
Incidence and long-term significance of transient ST segment
deviation in hemodialysis patients. Clin Nephrol
49:236-9, 1998.
1201. Marwick TH, Steinmuller DR, Underwood DA, Hobbs RE,
Go RT, Swift C y cols. Ineffectiveness of dipyridamole SPECT
thallium imaging as a sreening technique for coronary artery
disease in patients with end-stage renal failure.
Transplantation 49:100-103, 1990.
1202. Vandenberg BF, Rossen JD, Grover-McKay M, Shammas NW,
Burns TL, Rezai K.Evaluation of diabetic patients for renal
and pancreas transplantation:Noninvasive screening for
coronary artery disease using radionuclide methods.
Transplantation 62:1230-1235, 1996.
1203. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ.
Prognostic value of myocardial perfusion studies in patients
with end-stage renal disease assessed for kidney or kidneypancreas
transplantation: a meta-analysis. J Am Soc Nephrol
14:431-439, 2003.
1204. Rostand SG, Rutsky EA. Ischemic heart disease in chronic
renal failure: Management considerations. Semin Dial 2:98-
101, 1989.
1205. Herzog CA MT, Pheley AM, White CW, White CW, Rao VK,
Dick CD. Dobutamine stress echocardiography for the
detection of significant coronary artery disease in renal
transplant candidates. Am J Kidney Dis 33:1080-90, 1999.
1206. Reis GMP, Leichtman AB, Merion RM, Merion RM, Fay WP,
Werns SW, y cols. Usefulness of dobutamine stress echocardiography
in detecting coronary artery disease in end-stage
renal disease. Am J Cardiol 75:707-10, 1995.
1207. Keeley EC, McCullough PA. Coronary revascularization in
patients with end-stage renal disease: Risks, Benefits and
Optimal Strategies. Rev Cardiovasc Med 4:125-130, 2003.
1208. Opsahl JA, Husebye DG, Helseth HK, Collins AJ. Coronary
artery bypass surgery in patients on maintenance dialysis:
long-term survival. Am J Kidney Dis 12:271-274, 1988.
1209. Kadakia RA, McCullough PA, Soman S . Does percutaneous
revascularization confer a long-term survival benefit in
patients with chronic renal failure? J Invasive Cardiol 12(11):
P1, 2000.
1210. Charra B, Calemard M, Laurent G. Importance of treatment
time and blood pressure control in achieving long-term survival
on dialysis. Am J Nephrol 16:35-44, 1996.
1211. Wizemann V. Points to remember when dialysing the patient
with coronary disease. Nephrol Dial Transplant 11:236-238,
1996.
1212. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis
patients receiving trombolytic therapy for acute myocardial
infarction in the U.S. Circulation 100 (suppl 1): 304 (abstract),
1999.
1213. Gottlieb SS, McCarter RJ, Vogel RA. Effect of betablockade
on mortality among high-risk and low-risk patient after myocardial
infarction. N Engl J Med 339:489-493, 1998.
1214. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G,
Pavese F, Iacono A. Dilated cardiomyopathy in dialysispatients
beneficial effects of carvedilol: A double-blind, placebo-controlled
trial. J Am Coll Cardiol 37: 407-411, 2001.
1215. Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto
A,Cittadini A y cols. Carvedilol increases two-year survival
in patients with dilated cardiomyopathy. A prospective, placebo-controlled
trial. J Am Coll Cardiol 41:1438-1444,
2003.
1216. Yusuf S, Zhao F, Mehta SR, chrolavicius S, Tognoni G, Fox KK.
Effects of clopidogrel in additon to aspirin in patietns with
acute coronary syndromes without ST-segment elevation. N
Engl J Med 345:494-502, 2001.
1217. Kong TQ, Dacanay S, Hsieh AA. Features of acute myocardial
infarction in patients on chronic hemodialysis (abstract).
Circulation 88(suppl 1): I-49 , 1993.
1218. Amann K, Ritz E. Cardiac disease in chronic uremia.
Pathophysiology. Adv Renal Replace Ther 4:212-224, 1997.
1219. Ritz E, Amann Tornig J, Schwarz U, Stein G. Some cardiac
abnormalities in renal failure. Adv Nephrol Necker Hosp
27:85-103, 1997.
1220. Amann K, Buzello M, Simonaviciene A, Miltenberger-
Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G,
Ritz E. Capillary/myocyte mismatch in the heart in renal failure-A
role for erythropoietin? Nephrol Dial Transplant
15:964-969, 2000.
1221. Herzog CA. Cardiac arrest in dialysis patients: Approaches to
alter an abysmal outcome. Kidney Int 84: S197-S200, 2003.
1222. Bleyer AK, Russell GB, Satko SG. Sudden an cardiac death
rates in hemodialysis patients. Kidney Int 55: 1553-1559,
1999.
1223. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C,
Lazarus JM y cols. Cardiac arrest and sudden death in dialysis
units. Kidney Int 60:350-357, 2001.
1224. Stevinkel P, Pecoits-Filho R, Lindholm B. Coronary artery
disease in end-stage renal disease: No longer a simple plumbing
problem. J Am Soc Nephrol 14:1927-1939, 2003.
1225. Chang JW, Yang WS, Min WK, Lee SK, Park JD, Kim SB.
Effects of statins on high-sensitivity C-reactive protein and
serum albumin in hemodialysis patients. Am J Kidney Dis
39:1213-1217, 2002.
1226. Dogra GK, Watts GF, Hermann S, Thomas MA, Irish AB.
Statin therapy improves brachial artery endothelial function
in nephrotic syndrome. Kidney Int 62:550-557, 2002.
1227. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J,
Nilsson J. Pravastatin treatment increases collagen content
and decreases lipid content, inflammation, metalloproteinases
and cell death in human carotid plaques: Implications for
plaque stabilisation. Circulation 103:926-933, 2001.
1228. De Cavanagh EM, Ferder L, Carrasquedo F,Scrivo D,
Wasserman A, Fraga CG y cols. Higher levels of antioxidant
defensers in enalapril-treated versus non-enalapril-treated
hemodialysis patients. Am J Kidney Dis 34:445-455, 1999.
1229. Steinberg D, Witztum JL. Is the oxidative modification hypothesis
relevant to human atherosclerosis? Do the antioxidant
trials conducted to date refute the hypothesis? Circulation
105:2107-2111, 2002.
1230. Boaz M, Smetana S, Weinstein T, Matas Z,Gafter U, Iaina A
y cols. Secondary prevention with antioxidants of cardiovasculr
disease in enstage renal disease (SPACE): randomised
placebo-controlled trial. Lancet 356:1213-1218, 2000.
1231. Tepel M, van der GM, Statz M, Jankowski K, Zidek W. The
antioxidant acetylcysteine reduces cardiovascular events in
patients with end-stage renal failure: A randomized, controlled
trial. Circulation 107:992-995, 2003.
1232. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams
K, Freed MI. Effect of rosiglitazone treatment on nontraditional
markers of cardiovascular disease in patients with type 2
diabetes mellitus. Circulation 106: 679-684, 2002.
224